Lyell Immunopharma (LYEL) FCF Margin (2020 - 2026)
Lyell Immunopharma (LYEL) reported FCF Margin of 1929950.0% for Q1 2026, down 114576429.0% on a YoY basis from N/an in Q1 2025, and down 250.57% sequentially from 550516.67% in Q4 2025.
Lyell Immunopharma (LYEL) FCF Margin (2020 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 7 years of FCF Margin data on file, last reported at 1929950.0% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin fell 114576429.0% year-over-year to 1929950.0%; the trailing twelve-month figure through Mar 2026 stood at 433903.23% (down 16408015.0% YoY), and the FY2025 full-year result was 418900.0%, down 15244426.0% from the prior year.
- FCF Margin declined to 1929950.0% in Q1 2026, from 550516.67% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 45.26% in Q4 2022 to a low of 1929950.0% in Q1 2026.
- A 5-year average of 505406.79% and a median of 293184.62% in 2024 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin plunged 177391633 bps in 2022 and soared 163391200 bps in 2023, its largest moves.
- Tracing LYEL's FCF Margin over 5 years: stood at 45.26% in 2022, then sank by 736192 bps to 333223.08% in 2023, then fell by 28 bps to 426963.64% in 2024, then dropped by 29 bps to 550516.67% in 2025, then slumped by 251 bps to 1929950.0% in 2026.
- Business Quant data shows LYEL's FCF Margin at 1929950.0% in Q1 2026, 550516.67% in Q4 2025, and 187753.33% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Lyell Immunopharma | 276.08 Mn | 276.08 Mn | - | -1,929,950.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,929,950.00% |
| Dec 31, 2025 | -550,516.67% |
| Sep 30, 2025 | -187,753.33% |
| Jun 30, 2025 | -433,962.50% |
| Mar 31, 2025 | -784,185.71% |
| Dec 31, 2024 | -426,963.64% |
| Sep 30, 2024 | -104,152.94% |
| Jun 30, 2024 | -293,184.62% |
| Mar 31, 2024 | -1,401,533.33% |
| Dec 31, 2023 | -333,223.08% |
| Sep 30, 2023 | -140,888.00% |
| Jun 30, 2023 | -148,496.30% |
| Mar 31, 2023 | -73,453.85% |
| Dec 31, 2022 | -45.26% |
| Sep 30, 2022 | -1,774,800.00% |
| Jun 30, 2022 | -133.68% |
| Mar 31, 2022 | -8,672.51% |
| Dec 31, 2021 | -3,305.63% |
| Sep 30, 2021 | -883.67% |
| Jun 30, 2021 | -1,026.75% |